Protagonist Therapeutics Inc近日获得投资银行Leerink Partners的首次研究覆盖。Leerink Partners对该公司给出"跑赢大盘"评级,并设定目标价为73美元。
这一评级表明分析师看好Protagonist Therapeutics Inc的发展前景,认为其股价表现将优于大盘整体水平。
Protagonist Therapeutics Inc近日获得投资银行Leerink Partners的首次研究覆盖。Leerink Partners对该公司给出"跑赢大盘"评级,并设定目标价为73美元。
这一评级表明分析师看好Protagonist Therapeutics Inc的发展前景,认为其股价表现将优于大盘整体水平。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.